(NASDAQ: STRO) Sutro Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.05%.
Sutro Biopharma's earnings in 2026 is -$155,268,000.On average, 16 Wall Street analysts forecast STRO's earnings for 2026 to be -$145,385,197, with the lowest STRO earnings forecast at -$167,964,776, and the highest STRO earnings forecast at -$111,212,852. On average, 16 Wall Street analysts forecast STRO's earnings for 2027 to be -$115,071,020, with the lowest STRO earnings forecast at -$169,153,437, and the highest STRO earnings forecast at -$59,789,982.
In 2028, STRO is forecast to generate -$116,857,332 in earnings, with the lowest earnings forecast at -$163,181,909 and the highest earnings forecast at -$43,578,704.